Research programme: natural killer cell stimulants - Innate Pharma/Novo Nordisk

Drug Profile

Research programme: natural killer cell stimulants - Innate Pharma/Novo Nordisk

Alternative Names: IPH 22XX; IPH 24

Latest Information Update: 21 Mar 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Innate Pharma; Novo Nordisk
  • Developer Innate Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation
  • Discontinued Cancer

Most Recent Events

  • 25 Aug 2010 Preclinical development is ongoing for Inflammation in Europe
  • 06 Oct 2008 Discontinued - Preclinical for Cancer in Europe (Parenteral)
  • 23 May 2008 Preclinical trials in Autoimmune disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top